Tracy Johnson
Medical · Lexington, KYNPI 1568820629
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,703 of the $4,825 with a category attached, or 76.7%. Teva Pharmaceuticals USA, Inc. accounts for 78.4% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $3,804, 9.2 times the $412 reported in 2021.
Across 58 payments — averaging $83.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$4K
- AbbVie$204
- GSK$129
- Bayer$120
- AstraZeneca$119
- Dexcom, Inc.$114
- plus $354 from 11 others
What the payments were for
- Speaking & faculty fees$3,70377%
- Food & beverage$1,12223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $3,785 |
| AbbVie | 14 | $204 |
| GSK | 7 | $129 |
| Bayer | 6 | $120 |
| AstraZeneca | 8 | $119 |
| Dexcom, Inc. | 1 | $114 |
| Novo Nordisk | 4 | $64 |
| Amgen | 3 | $51 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Merck | 2 | $39 |
| Lilly USA, LLC | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $28 |
| Abbott | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$3,703
- DEXCOM G7 GSS (161)$114
How this compares
$4,825 in reported general payments places this provider in the 85th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 15 | $285 |
| Levothyroxine Sodium | 14 | $128 |
| Pantoprazole Sodium | 14 | $119 |
| Estradiol | 11 | $94 |
| Glipizide ErGlipizide | 11 | $78 |
| Buspirone Hcl | 15 | $75 |
| Simvastatin | 21 | $72 |
| Lisinopril | 21 | $61 |
| Rosuvastatin Calcium | 13 | $56 |
| Ondansetron Hcl | 11 | $46 |
| Metformin Hcl ErMetformin Hcl | 11 | $39 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other medical in Lexington
- Chasity HesterLexington$16K
- Allison ScottLexington$8K
- Micah BuckelLexington$7K
- Rebecca KraftickLexington$6K
- Anna SchaeferLexington$6K
- Christen MontgomeryLexington$5K
- Sarah GrimmLexington$5K
- Whitney WhitakerLexington$4K
- Hannah BurfordLexington$4K
- Kathryn AllenLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.